TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Nov 30, 2022 09:31 JST
Source:
Biogen
Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine
TOKYO, Nov 30, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, were published in the New England Journal of Medicine, one of the world's most prestigious peer-reviewed medical journals. For the details of the paper, please refer to: www.nejm.org/doi/full/10.1056/NEJMoa2212948.
The rapid publication of the Clarity AD study results demonstrates Eisai's strong commitment to trust and transparency based on Eisai's human health care mission. Eisai and Biogen remain committed to disclosing data and information on lecanemab. If approved, we will work to bring the drug expeditiously to people living with early AD and their families.
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such an investigational agent will successfully gain health authority approval.
For more information, visit www.eisai.com/news/2022/pdf/enews202284pdf.pdf.
Source: Biogen
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
January 27 2023 10:46 JST
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
January 19 2023 09:35 JST
Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company
January 19 2023 08:07 JST
Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023
January 18 2023 12:28 JST
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan
January 16 2023 17:56 JST
Eisai Launches Renewed Sustainability Page
January 13 2023 14:06 JST
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe
January 11 2023 11:52 JST
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
January 09 2023 20:55 JST
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
January 09 2023 19:40 JST
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
December 22 2022 17:07 JST
More Press release >>
Latest Press Release
Toyota Tsusho, IIJ, NEC, and NTT Com Sign Contract with Uzbektelecom for Telecommunications Infrastructure Development Project
Jan 27, 2023 15:25 JST
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
Jan 27, 2023 11:46 JST
TMC Announces Changes to Executive Structure
Jan 27, 2023 10:59 JST
Nippon Steel, Mitsubishi Corporation and ExxonMobil to Evaluate and Establish CCS Value Chains in the Asia Pacific Region
Jan 26, 2023 19:16 JST
Kurita Water Industries and Hitachi Launch a Co-creation to Implement Solution in Society and Build an Ecosystem for a Sustainable Society with "Zero Environmental Impact"
Jan 26, 2023 19:02 JST
Four Companies Announce Joint Feasibility Study of Large-Scale and Wide-Area Carbon Capture and Storage (CCS) Value Chain Project Using Ship Transportation
Jan 26, 2023 18:28 JST
Mitsubishi Power Receives Order for H-25 Gas Turbine for Taiwan's Chang Chun Petrochemical
Jan 26, 2023 18:22 JST
Fujitsu and Mizuho Bank embark on collaboration for sustainable management information services
Jan 26, 2023 13:44 JST
All-New eK X EV Earns Top Rating in Vehicle Safety Performance 2022 Car Assessment by JNCAP
Jan 26, 2023 09:01 JST
DOCOMO Announces World's First Technology that Utilizes Human-Augmentation Platform for Sharing Haptic Information Between People
Jan 25, 2023 17:17 JST
EEJA (TANAKA Precious Metals) to Exhibit at 37th INTERNEPCON JAPAN
Jan 25, 2023 11:00 JST
EEJA (TANAKA Precious Metals) to Exhibit at 37th INTERNEPCON JAPAN
Jan 25, 2023 11:00 JST
Hitachi Astemo, Trend Micro, and VicOne Expand Collaboration on Security Solutions for Connected Cars, Targeting 2025 Commercialization
Jan 25, 2023 09:02 JST
Honda to Make Organizational Changes (Effective April 1, 2023) to Further Accelerate Electrification Business and Realize New Value Creation
Jan 24, 2023 17:18 JST
Honda and GS Yuasa Reach Basic Agreement Toward Collaboration for a High-capacity, High-output Lithium-ion Battery
Jan 24, 2023 16:02 JST
KDDI starts commercial deployment of 5G Open vRAN sites in Japan in collaboration with Samsung Electronics and Fujitsu Limited
Jan 24, 2023 10:22 JST
Nurburgring gives green light for a comprehensive digitization measure of the world-famous Nordschleife
Jan 23, 2023 16:55 JST
NBB and JCB Enable the Acceptance of JCB Cards Through its POS & E-Commerce Merchants in The Kingdom of Bahrain
Jan 23, 2023 15:00 JST
JCB starts Red Guahan Shuttle Free Ride Campaign in Guam
Jan 23, 2023 12:00 JST
Ogier claims ninth Monte win in TOYOTA GAZOO Racing one-two
Jan 23, 2023 11:23 JST
More Latest Release >>